Search research articles
Contact Us
Filters
Showing results (61-70 of 64) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 64 results.
La Revue De Medecine Interne
|
February 15, 2008
[Cholangiocarcinoma: epidemiology and global management]
C Dreyer, C Le Tourneau, S Faivre, et al.
Clinical and Translational Gastroenterology
|
July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
R K Kelley, E Gane, E Assenat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2000
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies
J P Delord, E Raymond, M Chaouche, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2016
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
S Faivre, P Niccoli, D Castellano, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 64) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 64 results.
La Revue De Medecine Interne
|
February 15, 2008
[Cholangiocarcinoma: epidemiology and global management]
C Dreyer, C Le Tourneau, S Faivre, et al.
Clinical and Translational Gastroenterology
|
July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
R K Kelley, E Gane, E Assenat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2000
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies
J P Delord, E Raymond, M Chaouche, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2016
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
S Faivre, P Niccoli, D Castellano, et al.
Page
of 7